Better understanding of AML biology and survival tactics has facilitated a wave of newly approved drugs against AML and also revealed a range of targets to be exploited for treatment. In our review, we discuss what these new targets are and how targeting them in combination might be beneficial.

Advances in multiple myeloma (MM) therapies have enhanced the likelihood of achieving deeper treatment responses which in turn carry significant prognostic implications.

Implications of RNA editing on chronic lymphocytic leukemia